Keywords: AstraZeneca, Palatin, Obesity drug, AZD2820, Roche, Cipla, Tarceva, Erlocip, Patent, India, High Court

AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute

Article | 10 September 2012

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has told its development partner Palatin Technologies (NYSE PTN) that it has decided to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in